Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium

BACKGROUND: Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β(2)-agonist for the treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind study compared the bronchodilator efficacy of indacaterol with that of placebo and tiotropium in patients with mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogelmeier, Claus, Ramos-Barbon, David, Jack, Damon, Piggott, Simon, Owen, Roger, Higgins, Mark, Kramer, Benjamin
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964613/
https://www.ncbi.nlm.nih.gov/pubmed/20920365
http://dx.doi.org/10.1186/1465-9921-11-135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964613/
https://www.ncbi.nlm.nih.gov/pubmed/20920365
http://dx.doi.org/10.1186/1465-9921-11-135

Ejemplares similares